Showing results (441-450 of 467) with videos related to
Sort By:
Pageof 47
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2020
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III TrialRichard T Penson, Ricardo Villalobos Valencia, David Cibula, et al.Pediatric Emergency Care|May 22, 2025
Racial and Ethnic Differences in ED Analgesia Among Injured Children Transported Via EMSSarahjean Kerolle, Lorin R Browne, Ruta Brazauskas, et al.Gynecologic Oncology|November 13, 2024
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancerKatherine Elizabeth Francis, Sandy Simon, Val Gebski, et al.Cancer Gene Therapy|June 10, 2006
Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status reportJ S Norris, A Bielawska, T Day, et al.Circulation|August 10, 2011
Striking In vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitroHiroshi Watanabe, Tao Yang, Dina Myers Stroud, et al.The Journal of Infectious Diseases|November 14, 1997
Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeastR S Lowe, D R Brown, J T Bryan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2024
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival ResultsGiovanni Scambia, Ricardo Villalobos Valencia, Nicoletta Colombo, et al.The Lancet. Oncology|October 29, 2021
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trialSusana Banerjee, Kathleen N Moore, Nicoletta Colombo, et al.The Lancet. Oncology|December 8, 2014
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialAmit M Oza, David Cibula, Ana Oaknin Benzaquen, et al.The Lancet. Oncology|July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialEric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.Pageof 47